Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Seminars in Immunopathology
Published in: Seminars in Immunopathology 4/2014

01-07-2014 | Review

Immunopathology of lupus nephritis

Authors: Hans-Joachim Anders, Agnes B. Fogo

Published in: Seminars in Immunopathology | Issue 4/2014

Login to get access

Abstract

When patients with systemic lupus erythematosus (SLE) present with urinary abnormalities, a renal biopsy is usually needed to rule out or confirm lupus nephritis. Renal biopsy is also needed to define the type of renal manifestation as different entities are associated with different outcomes; hence, renal biopsy results shape lupus management. But why does lupus nephritis come in different shapes? Why do patients with SLE often show change over time in class of lupus nephritis or have mixed forms? How does autoimmunity in SLE evolve? Why does loss of tolerance against nuclear antigens preferentially affect the kidney? Why are immune complex deposits in different glomerular compartments associated with different outcomes? What determines crescent formation in lupus? In this review, we discuss these questions by linking the latest information on lupus pathogenesis into the context of the different classes of lupus nephritis. This should help the basic scientist, the pathologist, and the clinician to gain a more conceptual view on the immunopathology of lupus nephritis.
Literature
1.
Liu Z, Davidson A (2012) Taming lupus—a new understanding of pathogenesis is leading to clinical advances. Nat Med 18:871–882PubMedCentralPubMed
2.
Tsokos GC (2011) Systemic lupus erythematosus. N Engl J Med 365:2110–2121PubMed
3.
Manger K, Manger B, Repp R, Geisselbrecht M, Geiger A, Pfahlberg A, Harrer T, Kalden JR (2002) Definition of risk factors for death, end stage renal disease, and thromboembolic events in a monocentric cohort of 338 patients with systemic lupus erythematosus. Ann Rheum Dis 61:1065–1070PubMedCentralPubMed
4.
Hiepe F, Dorner T, Hauser AE, Hoyer BF, Mei H, Radbruch A (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7:170–178PubMed
5.
Goodnow CC (2007) Multistep pathogenesis of autoimmune disease. Cell 130:25–35PubMed
6.
7.
Migliorini A, Anders HJ (2012) A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 8:183–189PubMed
8.
Hakkim A, Furnrohr BG, Amann K, Laube B, Abu Abed U, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A (2010) Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 107:9813–9818PubMedCentralPubMed
9.
Kaplan MJ, Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao WP, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT (2011) Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 187:538–552PubMedCentralPubMed
10.
Garcia-Romo GS, Caielli S, Vega B, Connolly J, Allantaz F, Xu Z, Punaro M, Baisch J, Guiducci C, Coffman RL, Barrat FJ, Banchereau J, Pascual V (2011) Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 3:73ra20PubMedCentralPubMed
11.
Lande R, Ganguly D, Facchinetti V, Frasca L, Conrad C, Gregorio J, Meller S, Chamilos G, Sebasigari R, Riccieri V, Bassett R, Amuro H, Fukuhara S, Ito T, Liu YJ, Gilliet M (2011) Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 3:73ra19PubMedCentralPubMed
12.
Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ (2011) Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 187:538–552PubMedCentralPubMed
13.
Bosch X (2011) Systemic lupus erythematosus and the neutrophil. N Engl J Med 365:758–760PubMed
14.
Munoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M (2010) The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 6:280–289PubMed
15.
Kanta H, Mohan C (2009) Three checkpoints in lupus development: central tolerance in adaptive immunity, peripheral amplification by innate immunity and end-organ inflammation. Genes Immun 10(5):390–396PubMed
16.
Hom G, Graham RR, Modrek B, Taylor KE, Ortmann W, Garnier S, Lee AT, Chung SA, Ferreira RC, Pant PV, Ballinger DG, Kosoy R, Demirci FY, Kamboh MI, Kao AH, Tian C, Gunnarsson I, Bengtsson AA, Rantapaa-Dahlqvist S, Petri M, Manzi S, Seldin MF, Ronnblom L, Syvanen AC, Criswell LA, Gregersen PK, Behrens TW (2008) Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 358:900–909PubMed
17.
Moser KL, Kelly JA, Lessard CJ, Harley JB (2009) Recent insights into the genetic basis of systemic lupus erythematosus. Genes Immun 10:373–379PubMedCentralPubMed
18.
Cui Y, Sheng Y, Zhang X (2013) Genetic susceptibility to SLE: recent progress from GWAS. J Autoimmun 41:25–33PubMed
19.
Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23:307–336PubMed
20.
Caricchio R, McPhie L, Cohen PL (2003) Ultraviolet B radiation-induced cell death: critical role of ultraviolet dose in inflammation and lupus autoantigen redistribution. J Immunol 171:5778–5786PubMed
21.
Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B (1988) Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140:2197–2200PubMed
22.
Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M (1990) Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665–1673PubMed
23.
24.
Kariko K, Ni H, Capodici J, Lamphier M, Weissman D (2004) mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279:12542–12550PubMed
25.
Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, Wagner H, Schmid RM, Bauer S, Krug A (2006) U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 107:3229–3234PubMed
26.
Teichmann LL, Ols ML, Kashgarian M, Reizis B, Kaplan DH, Shlomchik MJ (2010) Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 33:967–978PubMedCentralPubMed
27.
Savarese E, Steinberg C, Pawar RD, Reindl W, Akira S, Anders HJ, Krug A (2008) Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 58:1107–1115PubMed
28.
Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A (2002) Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416:603–607PubMed
29.
Lau CM, Broughton C, Tabor AS, Akira S, Flavell RA, Mamula MJ, Christensen SR, Shlomchik MJ, Viglianti GA, Rifkin IR, Marshak-Rothstein A (2005) RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 202:1171–1177PubMedCentralPubMed
30.
Lech M, Kulkarni OP, Pfeiffer S, Savarese E, Krug A, Garlanda C, Mantovani A, Anders HJ (2008) Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 205:1879–1888PubMedCentralPubMed
31.
Lech M, Skuginna V, Kulkarni OP, Gong J, Wei T, Stark RW, Garlanda C, Mantovani A, Anders HJ (2010) Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J Pathol 220:596–607PubMed
32.
Garlanda C, Anders HJ, Mantovani A (2009) TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends Immunol 30:439–446PubMed
33.
Guiducci C, Gong M, Xu Z, Gill M, Chaussabel D, Meeker T, Chan JH, Wright T, Punaro M, Bolland S, Soumelis V, Banchereau J, Coffman RL, Pascual V, Barrat FJ (2010) TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 465:937–941PubMedCentralPubMed
34.
Patole PS, Zecher D, Pawar RD, Grone HJ, Schlondorff D, Anders HJ (2005) G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 16:3273–3280PubMed
35.
Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ (2007) Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 18:1721–1731PubMed
36.
Anders HJ (2009) Pseudoviral immunity—a novel concept for lupus. Trends Mol Med 15:553–561PubMed
37.
Marshak-Rothstein A, Rifkin IR (2007) Immunologically active autoantigens: the role of toll-like receptors in the development of chronic inflammatory disease. Annu Rev Immunol 25:419–441PubMed
38.
Chan OT, Hannum LG, Haberman AM, Madaio MP, Shlomchik MJ (1999) A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 189:1639–1648PubMedCentralPubMed
39.
Zikherman J, Parameswaran R, Weiss A (2012) Endogenous antigen tunes the responsiveness of naive B cells but not T cells. Nature 489:160–164PubMedCentralPubMed
40.
Allam R, Sayyed SG, Kulkarni O, Lichtnekert J, Anders HJ (2011) Murine double minute-2 drives systemic lupus erythematosus and lupus nephritis. J Am Soc Nephrol 22:2016–2027, in press
41.
42.
Gayed M, Gordon C (2010) Novel treatments for systemic lupus erythematosus. Curr Opin Investig Drugs 11:1256–1264PubMed
43.
Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15:241–250PubMed
44.
Mercadal L, Montcel ST, Nochy D, Queffeulou G, Piette JC, Isnard-Bagnis C, Martinez F (2002) Factors affecting outcome and prognosis in membranous lupus nephropathy. Nephrol Dial Transplant 17:1771–1778PubMed
45.
Schwartz MM, Korbet SM, Lewis EJ (2008) The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant 23:1298–1306PubMed
46.
Contreras G, Pardo V, Cely C, Borja E, Hurtado A, De La Cuesta C, Iqbal K, Lenz O, Asif A, Nahar N, Leclerq B, Leon C, Schulman I, Ramirez-Seijas F, Paredes A, Cepero A, Khan T, Pachon F, Tozman E, Barreto G, Hoffman D, Almeida Suarez M, Busse JC, Esquenazi M, Esquenazi A, Garcia Mayol L, Garcia Estrada H (2005) Factors associated with poor outcomes in patients with lupus nephritis. Lupus 14:890–895PubMed
47.
Hill GS, Delahousse M, Nochy D, Remy P, Mignon F, Mery JP, Bariety J (2001) Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 59:304–316PubMed
48.
Yu F, Wu LH, Tan Y, Li LH, Wang CL, Wang WK, Qu Z, Chen MH, Gao JJ, Li ZY, Zheng X, Ao J, Zhu SN, Wang SX, Zhao MH, Zou WZ, Liu G (2010) Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 77:820–829PubMed
49.
Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21PubMedCentralPubMed
50.
Dube GK, Markowitz GS, Radhakrishnan J, Appel GB, D'Agati VD (2002) Minimal change disease in systemic lupus erythematosus. Clin Nephrol 57:120–126PubMed
51.
Kraft SW, Schwartz MM, Korbet SM, Lewis EJ (2005) Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol 16:175–179PubMed
52.
Han TS, Schwartz MM, Lewis EJ (2006) Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus 15:71–75PubMed
53.
Barber C, Herzenberg A, Aghdassi E, Su J, Lou W, Qian G, Yip J, Nasr SH, Thomas D, Scholey JW, Wither J, Urowitz M, Gladman D, Reich H, Fortin PR (2012) Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 7:757–764PubMedCentralPubMed
54.
Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, Yu F, Liu G, Zhao MH (2013) The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 15:R12PubMedCentralPubMed
55.
Park MH, D'Agati V, Appel GB, Pirani CL (1986) Tubulointerstitial disease in lupus nephritis: relationship to immune deposits, interstitial inflammation, glomerular changes, renal function, and prognosis. Nephron 44:309–319PubMed
56.
Nath KA (1992) Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 20:1–17PubMed
57.
Hayakawa S, Nakabayashi K, Karube M, Arimura Y, Soejima A, Yamada A, Fujioka Y (2006) Tubulointerstitial immune complex nephritis in a patient with systemic lupus erythematosus: role of peritubular capillaritis with immune complex deposits in the pathogenesis of the tubulointerstitial nephritis. Clin Exp Nephrol 10:146–151PubMed
58.
59.
Yung S, Chan TM (2012) Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis—getting to know the unknown. Clin Dev Immunol 2012:139365PubMedCentralPubMed
60.
Mortensen ES, Rekvig OP (2009) Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 20:696–704PubMed
61.
Yung S, Cheung KF, Zhang Q, Chan TM (2010) Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 21:1912–1927PubMedCentralPubMed
62.
Zhao Z, Deocharan B, Scherer PE, Ozelius LJ, Putterman C (2006) Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin. J Immunol 176:7704–7714PubMed
63.
Mjelle JE, Rekvig OP, Van Der Vlag J, Fenton KA (2011) Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 44:373–383PubMed
64.
Fenton KA, Tommeras B, Marion TN, Rekvig OP (2010) Pure anti-dsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity 43:179–188PubMed
65.
Niederer HA, Clatworthy MR, Willcocks LC, Smith KG (2010) FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. Ann N Y Acad Sci 1183:69–88PubMed
66.
Sherer Y, Shoenfeld Y (2006) Intravenous immunoglobulin for immunomodulation of systemic lupus erythematosus. Autoimmun Rev 5:153–155PubMed
67.
Allam R, Lichtnekert J, Moll A, Taubitz A, Vielhauer V, Anders HJ (2009) Viral RNA and DNA sense common antiviral responses including type I interferons in mesangial cells. J Am Soc Nephrol 20:1986–1996, in pressPubMedCentralPubMed
68.
Fluer K, Allam R, Zecher D, Kulkarni O, Lichtnekert J, Schwarz M, Beutler B, Vielhauer V, Anders HJ (2009) Viral RNA induces type I interferon-dependent cytokine release and cell death in mesangial cells via MDA5. Implications for viral infection-associated glomerulonephritis. Am J Pathol 175:2014–2022, in press
69.
Hagele H, Allam R, Pawar RD, Anders HJ (2009) Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1. Nephrol Dial Transplant 24:3312–3318PubMed
70.
Hagele H, Allam R, Pawar RD, Reichel CA, Krombach F, Anders HJ (2009) Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway. Am J Pathol 175:1896–1904PubMedCentralPubMed
71.
Fairhurst AM, Xie C, Fu Y, Wang A, Boudreaux C, Zhou XJ, Cibotti R, Coyle A, Connolly JE, Wakeland EK, Mohan C (2009) Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 183:6831–6838PubMedCentralPubMed
72.
Anders HJ, Lichtnekert J, Allam R (2010) Interferon-alpha and -beta in kidney inflammation. Kidney Int 77:848–854PubMed
73.
Triantafyllopoulou A, Franzke CW, Seshan SV, Perino G, Kalliolias GD, Ramanujam M, van Rooijen N, Davidson A, Ivashkiv LB (2010) Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci U S A 107:3012–3017PubMedCentralPubMed
74.
Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de lema G, Strutz F, Bauer S, Rutz M, Wagner H, Grone HJ, Schlondorff D (2004) Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 18:534–536PubMed
75.
Kanapathippillai P, Hedberg A, Fenton CG, Fenton KA (2013) Nucleosomes contribute to increase mesangial cell chemokine expression during the development of lupus nephritis. Cytokine 62:244–252PubMed
76.
Tojo T, Friou GJ (1968) Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 161:904–906PubMed
77.
Sekine H, Kinser TT, Qiao F, Martinez E, Paulling E, Ruiz P, Gilkeson GS, Tomlinson S (2011) The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 63:1076–1085PubMedCentralPubMed
78.
Bao L, Haas M, Quigg RJ (2011) Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 22:285–295PubMedCentralPubMed
79.
Hugo C, Shankland SJ, Bowen-Pope DF, Couser WG, Johnson RJ (1997) Extraglomerular origin of the mesangial cell after injury. A new role of the juxtaglomerular apparatus. J Clin Invest 100:786–794PubMedCentralPubMed
80.
Migliorini A, Ebid R, Scherbaum CR, Anders HJ (2013) The danger control concept in kidney disease: mesangial cells. J Nephrol 26:437–449PubMed
81.
Hedberg A, Fismen S, Fenton KA, Fenton C, Osterud B, Mortensen ES, Rekvig OP (2011) Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheum 63:1065–1075PubMed
82.
Rich SA (1981) Human lupus inclusions and interferon. Science 213:772–775PubMed
83.
Moreth K, Brodbeck R, Babelova A, Gretz N, Spieker T, Zeng-Brouwers J, Pfeilschifter J, Young MF, Schaefer RM, Schaefer L (2010) The proteoglycan biglycan regulates expression of the B cell chemoattractant CXCL13 and aggravates murine lupus nephritis. J Clin Invest 120:4251–4272PubMedCentralPubMed
84.
Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, Yang H (2006) HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26:174–179PubMed
85.
Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hagele H, Lichtnekert J, Hagemann JH, Rupanagudi KV, Ryu M, Schwarzenberger C, Hohenstein B, Hugo C, Uhl B, Reichel CA, Krombach F, Monestier M, Liapis H, Moreth K, Schaefer L, Anders HJ (2012) Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol 23:1375–1388PubMedCentralPubMed
86.
Pawar RD, Castrezana-Lopez L, Allam R, Kulkarni OP, Segerer S, Radomska E, Meyer TN, Schwesinger CM, Akis N, Grone HJ, Anders HJ (2009) Bacterial lipopeptide triggers massive albuminuria in murine lupus nephritis by activating Toll-like receptor 2 at the glomerular filtration barrier. Immunology 128:e206–e221PubMedCentralPubMed
87.
Kulkarni O, Anders HJ (2008) Chemokines in lupus nephritis. Front Biosci 13:3312–3320PubMed
88.
Kulkarni O, Pawar RD, Purschke W, Eulberg D, Selve N, Buchner K, Ninichuk V, Segerer S, Vielhauer V, Klussmann S, Anders HJ (2007) Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 18:2350–2358PubMed
89.
Perez de Lema G, Maier H, Franz TJ, Escribese M, Chilla S, Segerer S, Camarasa N, Schmid H, Banas B, Kalaydjiev S, Busch DH, Pfeffer K, Mampaso F, Schlondorff D, Luckow B (2005) Chemokine receptor Ccr2 deficiency reduces renal disease and prolongs survival in MRL/lpr lupus-prone mice. J Am Soc Nephrol 16:3592–3601PubMed
90.
Anders HJ, Belemezova E, Eis V, Segerer S, Vielhauer V, Perez de Lema G, Kretzler M, Cohen CD, Frink M, Horuk R, Hudkins KL, Alpers CE, Mampaso F, Schlondorff D (2004) Late onset of treatment with a chemokine receptor CCR1 antagonist prevents progression of lupus nephritis in MRL-Fas(lpr) mice. J Am Soc Nephrol 15:1504–1513PubMed
91.
Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A, Camussi G (2003) The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 170:1466–1472PubMed
92.
Deban L, Russo RC, Sironi M, Moalli F, Scanziani M, Zambelli V, Cuccovillo I, Bastone A, Gobbi M, Valentino S, Doni A, Garlanda C, Danese S, Salvatori G, Sassano M, Evangelista V, Rossi B, Zenaro E, Constantin G, Laudanna C, Bottazzi B, Mantovani A (2010) Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 11:328–334PubMed
93.
Clark MR, Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, Kaverina N, Utset TO, Meehan SM, Quigg RJ, Meffre E (2011) In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 186:1849–1860PubMedCentralPubMed
94.
Lacotte S, Decossas M, Le Coz C, Brun S, Muller S, Dumortier H (2013) Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice. PLoS One 8:e58140PubMedCentralPubMed
95.
Neusser MA, Lindenmeyer MT, Edenhofer I, Gaiser S, Kretzler M, Regele H, Segerer S, Cohen CD (2011) Intrarenal production of B-cell survival factors in human lupus nephritis. Mod Pathol 24:98–107PubMed
96.
Espeli M, Bokers S, Giannico G, Dickinson HA, Bardsley V, Fogo AB, Smith KG (2011) Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 22:296–305PubMedCentralPubMed
97.
Chang A, Henderson SG, Brandt D, Liu N, Guttikonda R, Hsieh C, Kaverina N, Utset TO, Meehan SM, Quigg RJ, Meffre E, Clark MR (2011) In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 186:1849–1860PubMedCentralPubMed
98.
Bekar KW, Owen T, Dunn R, Ichikawa T, Wang W, Wang R, Barnard J, Brady S, Nevarez S, Goldman BI, Kehry M, Anolik JH (2010) Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum 62:2443–2457PubMedCentralPubMed
99.
Ramanujam M, Bethunaickan R, Huang W, Tao H, Madaio MP, Davidson A (2010) Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 62:1457–1468PubMedCentralPubMed
100.
Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y, Bottinger EP, Ivashkiv L, Kretzler M, Davidson A (2011) A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 186:4994–5003PubMedCentralPubMed
101.
Katsiari CG, Liossis SN, Sfikakis PP (2010) The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum 39:491–503PubMed
102.
Apostolidis SA, Crispin JC, Tsokos GC (2011) IL-17-producing T cells in lupus nephritis. Lupus 20:120–124PubMed
103.
Steinmetz OM, Turner JE, Paust HJ, Lindner M, Peters A, Heiss K, Velden J, Hopfer H, Fehr S, Krieger T, Meyer-Schwesinger C, Meyer TN, Helmchen U, Mittrucker HW, Stahl RA, Panzer U (2009) CXCR3 mediates renal Th1 and Th17 immune response in murine lupus nephritis. J Immunol 183:4693–4704PubMed
104.
Moser K, Kalies K, Szyska M, Humrich JY, Amann K, Manz RA (2012) CXCR3 promotes the production of IgG1 autoantibodies but is not essential for the development of lupus nephritis in NZB/NZW mice. Arthritis Rheum 64:1237–1246PubMed
105.
Ryu M, Migliorini A, Miosge N, Gross O, Shankland S, Brinkkoetter PT, Hagmann H, Romagnani P, Liapis H, Anders HJ (2014) Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury. J Pathol. doi:10.​1002/​path.​4046
106.
Bollee G, Flamant M, Schordan S, Fligny C, Rumpel E, Milon M, Schordan E, Sabaa N, Vandermeersch S, Galaup A, Rodenas A, Casal I, Sunnarborg SW, Salant DJ, Kopp JB, Threadgill DW, Quaggin SE, Dussaule JC, Germain S, Mesnard L, Endlich K, Boucheix C, Belenfant X, Callard P, Endlich N, Tharaux PL (2011) Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 17:1242–1250PubMedCentralPubMed
107.
Smeets B, Angelotti ML, Rizzo P, Dijkman H, Lazzeri E, Mooren F, Ballerini L, Parente E, Sagrinati C, Mazzinghi B, Ronconi E, Becherucci F, Benigni A, Steenbergen E, Lasagni L, Remuzzi G, Wetzels J, Romagnani P (2009) Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol 20:2593–2603PubMedCentralPubMed
108.
Smeets B, Uhlig S, Fuss A, Mooren F, Wetzels JF, Floege J, Moeller MJ (2009) Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol 20:2604–2615PubMedCentralPubMed
109.
Yu F, Tan Y, Liu G, Wang SX, Zou WZ, Zhao MH (2009) Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 76:307–317PubMed
110.
Bonsib SM (1984) Scanning electron microscopy of acellular glomeruli in human glomerulonephritis: application of a technique. Ultrastruct Pathol 7:215–217PubMed
111.
Pippin JW, Durvasula R, Petermann A, Hiromura K, Couser WG, Shankland SJ (2003) DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. J Clin Invest 111:877–885PubMedCentralPubMed
112.
Shankland SJ, Pippin JW, Couser WG (1999) Complement (C5b-9) induces glomerular epithelial cell DNA synthesis but not proliferation in vitro. Kidney Int 56:538–548PubMed
113.
Liapis H, Romagnani P, Anders HJ (2013) New insights into the pathology of podocyte loss: mitotic catastrophe. Am J Pathol 183(5):1364–1374PubMedCentralPubMed
114.
Nangaku M, Shankland SJ, Couser WG (2005) Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 16:1195–1204PubMed
115.
Wharram BL, Goyal M, Wiggins JE, Sanden SK, Hussain S, Filipiak WE, Saunders TL, Dysko RC, Kohno K, Holzman LB, Wiggins RC (2005) Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 16:2941–2952PubMed
116.
Ronconi E, Sagrinati C, Angelotti ML, Lazzeri E, Mazzinghi B, Ballerini L, Parente E, Becherucci F, Gacci M, Carini M, Maggi E, Serio M, Vannelli GB, Lasagni L, Romagnani S, Romagnani P (2009) Regeneration of glomerular podocytes by human renal progenitors. J Am Soc Nephrol 20:322–332PubMedCentralPubMed
117.
Appel D, Kershaw DB, Smeets B, Yuan G, Fuss A, Frye B, Elger M, Kriz W, Floege J, Moeller MJ (2009) Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 20:333–343PubMedCentralPubMed
118.
Lasagni L, Romagnani P (2010) Glomerular epithelial stem cells: the good, the bad, and the ugly. J Am Soc Nephrol 21:1612–1619PubMed
119.
Peired A, Angelotti ML, Ronconi E, la Marca G, Mazzinghi B, Sisti A, Lombardi D, Giocaliere E, Della Bona M, Villanelli F, Parente E, Ballerini L, Sagrinati C, Wanner N, Huber TB, Liapis H, Lazzeri E, Lasagni L, Romagnani P (2013) Proteinuria impairs podocyte regeneration by sequestering retinoic acid. J Am Soc Nephrol 24(11):1756–1768PubMedCentralPubMed
120.
Ryu M, Mulay SR, Miosge N, Gross O, Anders HJ (2012) Tumour necrosis factor-alpha drives Alport glomerulosclerosis in mice by promoting podocyte apoptosis. J Pathol 226:120–131PubMed
121.
Migliorini A, Angelotti ML, Mulay SR, Kulkarni OO, Demleitner J, Dietrich A, Sagrinati C, Ballerini L, Peired A, Shankland SJ, Liapis H, Romagnani P, Anders HJ (2013) The antiviral cytokines IFN-alpha and IFN-beta modulate parietal epithelial cells and promote podocyte loss: implications for IFN toxicity, viral glomerulonephritis, and glomerular regeneration. Am J Pathol 183:431–440PubMed
122.
Smeets B, Kuppe C, Sicking EM, Fuss A, Jirak P, van Kuppevelt TH, Endlich K, Wetzels JF, Grone HJ, Floege J, Moeller MJ (2011) Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 22:1262–1274PubMedCentralPubMed
123.
Anders HJ (2012) Four danger response programs determine glomerular and tubulointerstitial kidney pathology: clotting, inflammation, epithelial and mesenchymal healing. Organogenesis 8:29–40PubMedCentralPubMed
124.
Kriz W, Lemley KV (1999) The role of the podocyte in glomerulosclerosis. Curr Opin Nephrol Hypertens 8:489–497PubMed
Metadata
Title
Immunopathology of lupus nephritis
Authors
Hans-Joachim Anders
Agnes B. Fogo
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Seminars in Immunopathology / Issue 4/2014
Print ISSN: 1863-2297
Electronic ISSN: 1863-2300
DOI
https://doi.org/10.1007/s00281-013-0413-5

Other articles of this Issue 4/2014

Seminars in Immunopathology 4/2014 Go to the issue

Review

Update on crescentic glomerulonephritis

Review

Immunopathogenesis of idiopathic nephrotic syndrome with relapse

Review

Immunopathogenesis of membranous nephropathy: an update

Review

The immunopathology of ANCA-associated vasculitis

Editorial

Ten-year advances in immunopathology of glomerulonephritis: translated into patients’ care or lost in translation?

Review

New insights into the pathogenesis of IgA nephropathy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits